About VectorY
VectorY is a fully integrated gene therapy company specializing in the development of novel therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a particular emphasis on muscle diseases. It combines the therapeutic potential of antibodies and gene therapy to create long-term therapeutic solutions for large disease areas with significant unmet medical need. VectorY was founded in the Amsterdam Science Park in August 2020.
Company details
Funding
Total raised
$175M
Last stage
Series A
Investors
Founders
Sander van Deventer
Physician-scientist with 25 years in drug development; played a critical role in developing the first commercial monoclonal antibody (Remicade) and first approved gene therapy in the West (Glybera); co-founder of uniQure and Forbion.
LinkedIn
Barbara Sanders
PhD in molecular virology (University of Amsterdam); over 10 years of experience in viral vector development; led development of the Ebola vaccine Zabdeno; inventor of eight patents.
LinkedInPavlina Konstantinova
Co-founder of VectorY Therapeutics, serving as Chief Scientific Officer.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.